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Objective: To characterize the socioeconomic and demographic aspects of sickle cell disease
patients from the state of Rio Grande do Norte (RN), Northeast Brazil, and their adherence
to  the recommended treatment.
Methods: This cross-sectional descriptive study was performed at referral centers for the
treatment of hematological diseases. One hundred and ﬁfty-ﬁve unrelated individuals with
sickle cell disease who went to these centers for outpatient visits were analyzed. All the
patients, or their caregivers, were informed about the research procedures and objectives,
and answered a standardized questionnaire.
Results: The patients were predominantly younger than 12 years old, self-declared as
mulatto,  lived in small towns fairly distant from the referral center, and had low educa-
tion  and socioeconomic levels. Individuals who were ten or younger were diagnosed at
an  earlier age. Almost 50% of the patients were taking hydroxyurea, 91.4% reported hav-
ing received pneumococcal/meningococcal vaccinations and 76.1% received penicillin as
antibiotic prophylaxis. However, the majority of them reported having difﬁculties follow-
ing the recommendations of the physicians, mainly in respect to attaining the prescribed
medications and transportation to the referral centers.
Conclusion: These individuals have a vulnerable socioeconomic situation that can lead to
an  aggravation of their general health and thus deserve special attention from the med-
ical  and psychosocial perspectives. Thus, it is necessary to improve public policies that
provide Brazilian sickle cell disease patients with better access to medical treatment, living
conditions, and integration into society.© 2015 Associac¸ão Bra
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ickle cell disease (SCD) is one of the most common severe
onogenic disorders worldwide.1 The underlying molecular
efect is a single nucleotide substitution (S – HBB; GAG>GTG;
lu → val; rs334) in the gene that encodes the -globin chain
f hemoglobin. The resulting hemoglobin S (Hb S) polymerizes
hen deoxygenated, causing polymer-associated lesions of
he red blood cells.1,2 SCD includes several different genotypes
ncluding sickle cell anemia (Hb SS) and compound heterozy-
otes of Hb S with -thalassemia (Hb S/-thal) or with other
ypes of hemoglobinopathies.3
The World Health Organization recognized SCD as a global
ublic health problem, as the overall number of babies born
ith SCD between 2010 and 2050 is estimated at about 14.24
illion.4 Data from the Ministry of Health estimates that
round 3500 children are born with sickle cell anemia each
ear in Brazil and the number of cases of the disease is
etween 25,000 and 30,000.5
The complications of this disease are numerous and can
ffect every organ and tissue in the body. The most common
omplications are pain crises, chronic anemia and its acute
xacerbations, stroke, acute chest syndrome, infection, pri-
pism, leg ulcerations, osteonecrosis, and cardiac and renal
roblems.6 Complications can be acute, producing dramatic
linical ﬁndings, or chronic, disabling, and cause premature
eath.2
Speciﬁc phenotypic manifestations of the disease vary con-
iderably in frequency and severity between patients and even
n the same patient over time.6 Both genetic and acquired fac-
ors contribute to this clinical variation. Among the acquired
actors, the most important is the patient’s socioeconomic
onditions.7
Knowledge of the demographic and socioeconomic proﬁle
f SCD patients is essential to identify their needs, to con-
ribute to improving resource allocation and to create and
mplement public health policies that beneﬁt this population.8
owever, studies that address these aspects of the disease
re relatively scarce in both the Brazilian and international
iterature.
Thus, this study aimed to characterize the demographic
nd socioeconomic aspects of SCD patients from the state of
io Grande do Norte (RN), a socioeconomic vulnerable area of
ortheastern Brazil, and their adherence to the recommended
reatment.
ethods
 cross-sectional descriptive study was performed at refer-
al centers for the treatment of hematological diseases in RN:
emocentro Dalton Cunha (Natal), Hospital Infantil Varela
antiago (Natal), and the Centro de Oncologia e Hematologia
e Mossoró (Mossoró). The participants were unrelated SCD
atients without cognitive impairment, who went to these
enters from March 2011 to October 2013 for outpatient visits.All the patients, or their caregivers, were informed about
he research procedures and objectives, and those who agreed
o participate in the study signed an informed consent form
nd answered a standardized questionnaire. When the patient 1 5;3  7(3):172–177 173
was younger than 18 years old, it was answered by the care-
giver.
The questions were orally asked by the interviewer with-
out inducing responses. Questions aimed to collect medical
history and the demographic and socioeconomic data of the
patient, including age, ethnicity, ancestry, residence, school-
ing, employment situation, family income, age at diagnosis,
use of hydroxyurea, prophylactic penicillin, immunization,
and difﬁculties in following treatment, among others. Clini-
cally relevant data were also taken directly from the patient’s
health records.
Data were collected in single individual interviews, and
after collection they were input into a Microsoft Excel 2010
spreadsheet. Frequency distribution tables were used for the
descriptive analysis of the categorical or nominal variables
and the signiﬁcance of differences between clinical character-
istics by age group were estimated using the Chi-squared (2)
or Fisher exact test, as appropriate. The comparison of the age
at diagnosis of SCD in age groups employed the Kruskal–Wallis
analysis of variance (ANOVA) test, followed by multiple com-
parisons of mean ranks, using the Statistica software (version
7). Differences with a p-value ≤0.05 were considered statisti-
cally signiﬁcant.
This study was conducted in accordance with the Helsinki
Declaration as revised in 2008, and was approved by the
Research Ethics Committee of the Universidade Federal do
Rio Grande do Norte (UFRN, under protocol number 193/09)
according to resolution 196/96 of the Conselho Nacional de
Saúde, Brazil.
Results
One hundred and seventy-seven patients with clinical and lab-
oratory diagnosis of SCD were interviewed. However, 22 were
ﬁrst- or second-degree relatives of other patients participating
in the study and were therefore excluded from the analysis.
Among the remaining 155 individuals, 109 (70.3%) had Hb SS,
23 (14.8%) were heterozygous for Hb S and -thalassemia, 21
(13.5%) were heterozygous for Hb S and Hb C, and two  (1.3%)
presented the association between Hb S and hereditary per-
sistence of fetal hemoglobin (HPFH).
The ages of the patients ranged from seven months to 48
years, with a median age of 12 years; the highest frequency
of individuals was in the age group ≤5 years (29.0%), followed
by the 11- to 15-year-old group (18.7%). The majority of the
individuals were male (52.9%), and self-declared as mulatto
(65.8%), but with no information about their ethnic ances-
try (83.9%). However, indigenous ancestry was predominant
(12.3%) among patients who informed their ancestry. A high
percentage of the patients (43.2%) lived in small towns, at least
60 km away from the referral centers (Table 1).
Of the over 18-year-old patients, 51.9% had not completed
high school, 50.0% were unemployed, and 19.2% were retired
or receiving social security beneﬁts. Most of the caregivers of
the under 18-year-old patients only completed primary school
education and the majority (55.3%) were working in regular
jobs. Most of the patients (52.7%) had a household income
of up to one minimum wage  in Brazil, about US$  240.00, and
one third (34.2%) did not receive any social beneﬁts from
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Table 1 – Demographic characteristics of sickle cell
disease patients.
Demographic characteristic n (%)
Age group (years)
≤5 45 (29.0)
6–10 22 (14.2)
11–15 28 (18.7)
16–20 23 (14.2)
21–30 23 (14.8)
31 14 (9.0)
Gender
Male 82 (52.9)
Female 73 (47.1)
Ethnicity
White 46 (29.7)
Mulatto 102 (65.8)
Black 7 (4.5)
Ancestrya
African 10 (6.5)
Indigenous 19 (12.3)
European 4 (2.6)
Did not know 130  (83.9)
Residence
Natal 45 (29.0)
Other towns in Natal Metropolitan region 27 (17.4)
Mossoró 16 (10.3)
Other towns of Rio Grande do Norte 67 (43.2)
a Four patients reported having indigenous and African ances-
Table 2 – Socioeconomic characteristics of the patients
with sickle cell disease analyzed in this study.
Socioeconomic
characteristic
Number of patients (%)
<18 yearsa ≥ 18 years Total
Schoolinga
Never Studied 5 (4.8) 3 (5.8) 8 (5.2)
Incomplete
primary school
35 (34.0) 15 (28.8) 50 (32.3)
Complete
primary school
26 (25.2) 9 (17.3) 35 (22.6)
Complete
secondary
education
31 (30.1) 24 (46.1) 55 (35.5)
Complete
higher
education
3 (2.9) 1 (1.9) 4 (2.6)
Did not answer 3 (2.9) – 3 (1.9)
Employment situationa
Working 57 (55.3) 14 (26.9) 71 (45.8)
Not working 22 (21.4) 26 (50.0) 48 (31.0)
Other 24 (23.2) 12 (23.0) 36 (23.2)
Household Income (Brazilian minimum wage)
Up to 1 81 (52.3)
From 1 to 2 13 (8.4)
From 2 to 3 53 (34.2)
More than 3 8 (5.2)
Beneﬁts from the federal governmentb
BPC-LOAS 58 (37.4)
Family
allowance
51 (32.9)
Others 8 (5.2)
Did not receive
social beneﬁts
53  (34.2)
a The schooling and employment situation of the caregivers was
considered.try, three reported indigenous and European, and one reported
African and European ancestry.
the government. Among those who did receive beneﬁts, the
Program of Continuous Cash Beneﬁt for Social Assistance
(BPC-LOAS) was the most prevalent (37.4% – Table 2).
The median age at diagnosis of SCD was eight months
(minimum: one month; maximum: eight years), two years
(minimum: one month; maximum: 14 years) and ﬁve years
(minimum: one month; maximum: 47 years) for individuals in
the under 11-year-old, 11- to 20-year-old, and over 20-year-old
age groups, respectively. A statistically signiﬁcant difference
was observed in the median age at diagnosis of SCD between
age groups (Figure 1).
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Figure 1 – Median age at diagnosis of sickle cell disease
stratiﬁed by age group.b 15 patients received both Program of Continuous Cash Beneﬁt for
Social Assistance (BPC-LOAS) and family allowance.
The majority of the patients (50.3%) reported having difﬁ-
culties following the recommendations of the physicians, in
particular difﬁculties to acquire the prescribed medications,
especially hydroxyurea, and transportation to the referral
centers when needed (Table 3).
Regarding the use of preventive measures against clin-
ical complications, it was observed that hydroxyurea was
Table 3 – Major difﬁculties reported by patients to follow
prescribed treatment.
Treatment difﬁculty n (%)
Achieve the prescribed medication 49 (31.6)
Transport to referral centers 27 (17.4)
Others 13 (8.4)
Did not have difﬁculties 77 (49.7)
Six patients reported difﬁculties to achieve the medication and to
go to the referral center, two reported problems in achieving the
medications and other reasons, and another three persons claimed
to have difﬁculties going to the referral center and other reasons.
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Table 4 – Use of preventive measures against clinical complications, according to age group.
Use of Hydroxyurea
n (5)
Vaccinationsb
n (5)
Prophylactic use of penicillin
n (5)
Yes No Yes No Yes No
Age group (years)
≤5 5 (11.1) 40 (88.9) 42 (93.3) 3 (6.7) 43 (95.6) 2 (4.4)
6–10 13 (59.1) 9 (40.9) 22 (100.0) 0 (0.0) 21 (95.5) 1 (4.5)
11–15 16 (57.1) 12 (42.9) 28 (100.0) 0 (0.0) 20 (71.4) 8 (28.6)
16–20 9 (39.1) 14 (60.9) 20 (95.2) 1 (4.8) 15 (65.2) 8 (34.8)
21–30 15 (65.2) 8 (34.8) 18 (78.3) 5 (21.7) 15 (65.2) 8 (34.8)
31 9 (64.2) 5 (35.7) 8 (66.7) 4 (33.3) 4 (28.5) 10 (71.4)
Total 67 (43.2) 88 (56.8) 138 (91.4) 13 (8.6) 118 (76.1) 37 (23.9)
p-value 0.000a 0.002a 0.000a
p-value Comparison of the use of preventive measures among the age groups calculated by Fisher Exact test.
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b Pneumococcal/meningococcal vaccinations (Four patients did not 
egularly used by 43.2% of the patients, with this percentage
eing signiﬁcantly lower in the youngest age group. Fur-
hermore, it was found that the majority (91.4%) of patients
eported having received pneumococcal/meningococcal vac-
inations and penicillin as antibiotic prophylaxis (76.1%).
owever, these percentages were much lower in the oldest age
roup and it was not possible to verify whether the vaccination
as  complete or incomplete for all patients (Table 4).
iscussion
CD is a chronic, degenerative and self-incapacitating dis-
ase affecting the patient and their family in an intense and
ermanent way. The clinical complications and the recur-
ent hospitalizations and blood transfusions, associated with
xternal domains such as unemployment, low income, and
ack of access to health services, negatively inﬂuence the life
f this population.7
People in a vulnerable socioeconomic situation are more
xposed to the determining social factors of the disease,
hich can lead to an aggravation of the patients’ general
ealth. Therefore, these individuals deserve special attention
n respect to medical and psychosocial perspectives.9
Rio Grande do Norte is a low-income area of Brazil, hav-
ng a Human Development Index of 0.684 (16th of all Brazilian
tates),10 an illiteracy rate of 19.8%, and a child mortality of
7.0%. Moreover, 62.6% of families have a monthly per capita
ncome of up to one minimum wage  (about US$ 240.00).11
In this study, patients were predominantly younger than
2 years, self-declared as mulatto and living in towns fairly
istant from referral centers for the treatment of SCD.
dditionally, more  than one third of the patients, or their care-
ivers, had only ﬁnished elementary school, were not working,
ad a very low household income, and were not receiving any
ocial beneﬁts from the government.
The age group proﬁle of this study was similar to that found
12y Maximo in Rio de Janeiro, Brazil. The predominance of
hildren and adolescents seems to demonstrate the severity
f the disease, with patients presenting low life expectancy,
espite important advances that emerged in the last decadesber if they had ever received pneumococcal vaccinations).
for the prevention and treatment of complications of the dis-
ease.
The predominance of mulattoes among patients is related
to the ethnic background of the population of the state of
Rio Grande do Norte according to the Brazilian Institute of
Geography and Statistics (IBGE),11 where the inﬂuence of
African slaves was not so strong as in some other Brazilian
states.13 The predominance of indigenous ancestry among the
patients who informed any ancestry corroborates this hypoth-
esis. However, many  studies worldwide have shown that SCD
is more  common in individuals of black ethnicity, that is,
African descent.5,14 Therefore, it is likely that the distribution
of this self-reported ethnicity may have been inﬂuenced not
only by the high degree of miscegenation, but also by  a certain
degree of bias of the individuals analyzed, who often prefer to
declare themselves as mulattoes instead of Blacks.
The low education level and socioeconomic status of
the patients were similar to those found in studies con-
ducted in England,15 the USA,16 Nigeria17 and other states of
Brazil.7,8,18,19 This generates a condition of social vulnerabil-
ity that affects the quality of life of patients and makes them
more  dependent on government programs for ﬁnancial bene-
ﬁts and health care. Additionally, one third of the analyzed
patients were not receiving any social beneﬁts, a situation
that impairs their living conditions even further. These vul-
nerable conditions also inﬂuence adherence to the treatment
recommended by the physician.20
Despite the complexity and multifactorial pathophysi-
ology of the disease, relatively straightforward measures
have greatly improved outcomes for children with SCD.
Such measures include early identiﬁcation of SCD by neona-
tal screening programs and the prompt establishment of
preventive measures with prophylactic penicillin and immun-
izations, and therapeutic interventions, such as transfusions
and hydroxyurea.21
This study showed that individuals who were under 11
years old were diagnosed at an earlier age. These results
demonstrate that the relatively recent implementation of
health policies have had a positive impact on the lives of
patients. It was also found that approximately half of the
patients (43.2%) were taking hydroxyurea. This percentage
oter.
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is higher than that reported by other studies conducted in
Brazil18,22 and the USA,23,24 and demonstrates good adher-
ence of the patients to treatment and the healthcare team’s
conﬁdence in the efﬁcacy of the medicine. However, only
11% of under 5-year-old children were taking hydroxyurea,
which seems to reﬂect the concerns about the overall safety
of this medicine, mainly in very young children. The results of
the Pediatrics Hydroxyurea Phase 3 Clinical Trial (Baby HUG)
demonstrated both safety and beneﬁcial effects of hydrox-
yurea in asymptomatic and symptomatic young children with
SCA, and suggests that clinicians should consider changing
their practice to prescribe hydroxyurea therapy for all very
young children with SCA, rather than treating only those most
severely affected.25
The rates of vaccination (91.4%) and prophylactic use of
penicillin (76.1%) found in this study also demonstrate good
adhesion of health staff and patients to general recommen-
dations for the treatment of SCD. Improved immunization
against Streptococcus pneumoniae and Haemophilus inﬂuenza,
and the use of penicillin prophylaxis have dramatically
reduced the frequency of serious bacterial infections and mor-
tality of infants with SCA.26,27
This immunization coverage of patients with SCD was sim-
ilar to those obtained by Frauches et al.28 in the state of Espírito
Santo, Brazil, and by Hardie et al.29 in patients from Jamaica.
On the other hand, the prophylactic use of penicillin was
higher than the rate reported by Warren et al.30 in the USA,
and similar to those described in others studies carried out in
Brazil31 and Jamaica.32 However it was not possible to directly
assess the vaccination record card of all individuals, nor ver-
ify adherence to prophylactic penicillin by other methods; it
is possible that our results are overestimated. Lower rates of
adherence to these practices in the older age groups can be
explained by the fact that these recommendations were estab-
lished in the 1980s and 1990s.
Despite this adherence to treatment and use of preven-
tive measures, a signiﬁcant percentage (31.6%) of patients
reported problems in achieving the prescribed medications,
especially hydroxyurea. The high costs of these medicines and
low socioeconomic status of patients make them dependent
on public programs for dispensing medicines. Therefore, the
occurrence of ﬁnancial and administrative problems in these
programs can make access to the recommended therapy quite
difﬁcult.
The distance to reference centers constitutes a barrier to
the implementation of a comprehensive care program for
SCD patients, as it generally restricts transportation to health
services.33 Added to this, the need to travel to get treatment
endangers patients’ lives. A study conducted by Fernandes
and Viana34 pointed out difﬁculties in getting transportation
to the health center as a contributing factor for premature
deaths of these individuals. In our study, almost half of the
analyzed individuals lived in towns fairly distant from the
referral centers and 17.4% reported difﬁculties in arriving at
the centers to perform the recommended treatment.
Therefore, it is necessary to improve public policies for
these individuals, taking into account their low socioeconomic
status, demographic characteristics, and difﬁculties in achiev-
ing the recommended treatment. And to be effective, these
measures need to provide psychosocial counseling necessary 2 0 1 5;3  7(3):172–177
for the development of the patient’s integration into society,
as well as access to medical treatment, allowing favorable
improvements in the reality experienced by Brazilians with
this disease.
Certain limitations of the current study should be taken
into account, especially with regard to adherence to the rec-
ommended medical treatment. As it was not possible to
analyze the vaccination record cards of all patients, we  were
not able to assess the adequacy of the vaccine program. Fur-
thermore, the use of hydroxyurea and prophylactic penicillin
was evaluated taking into account only the patients’ reports.
Therefore, their regular and proper use of these drugs could
not be proven.
Conclusions
SCD patients from the state of Rio Grande do Norte have
a vulnerable socioeconomic situation that can lead to an
aggravation of their general health and thus deserves spe-
cial attention from the medical and psychosocial perspectives.
Therefore, it is necessary to improve public policies that
provide Brazilians with SCD better access to medical treat-
ment, living conditions, and integration into society.
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